Chemical Technology

Silicone-Base Coating Mitigates Corrosion Under Insulation (CUI) In Petrochemical Plants

June 15, 2021

Corrosion under insulation (CUI) is one of the costliest problems in the petrochemical industry. It also presents a high degree of potential danger. CUI occurs when moisture mixed with contaminants infiltrates insulation, encouraging the development of corrosion cells on the steel underneath. This paper demonstrates how Sherwin-Williams Heat-Flex® High-Temp 1200 withstands temperature fluctuations, thermal shock and other upset conditions to protect against hidden CUI.

Spotlight

Juno Therapeutics, Inc.

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date.

OTHER WHITEPAPERS
news image

LATIN AMERICA PETROCHEMICALS AND CHEMICALS 2019

whitePaper | November 27, 2019

In this challenging environment, it is key for petrochemical and chemical producers to be efficient and to manage closely their production and logistics chains. We live in a world of product abundance as a result of the shale gas revolution, so the market will be taken by those who can be the most competitive. In this respect, the region needs to take advantage of its geological potential, with the pre-salt fields in Brazil and Argentina’s Vaca Muerta developments, as well as Mexico’s injection of funds to Pemex to help the state-oil company recover its past grandeur.

Read More
news image

Decarbonizing practices in the global food and beverage industry

whitePaper | December 24, 2022

This whitepaper examines the current state and trajectory of decarbonization within the global food and beverage industries. By examining and establishing a baseline on industry action, early-mid and long-term initiatives can be highlighted to help inform manufacturers and producers

Read More
news image

Foil Fluid Flow Frustrations

whitePaper | December 9, 2022

The International Society of Automation (ISA) working group responsible for ISA TR 96.05.01 2008 edition on partial stroke testing of automated valves published an update to the original technical report.

Read More
news image

U.S. Department of Commerce Economics and Statistics Administration

whitePaper | December 24, 2022

Chemical manufacturing shipments totaled $794.7 billion or 13.9 percent of all manufacturing shipments in 2012. According to the North American Industry Classification System (NAICS), the industry is engaged in the “transformation of organic and inorganic raw materials by a chemical process and the formulation of products.”

Read More
news image

Methods, and Solutions for Chemical Treatment of Industrial Water and Wastewater

whitePaper | March 2, 2023

Fresh water is used in a broad range of process applications including boiler water and cooling system water treatment, as well as food and beverage process water treatment, among others. The resulting wastewater must then be properly treated before discharge into local sewer systems.

Read More
news image

ChemDraw and Chemoffice+ Cloud tips and tricks v21

whitePaper | November 24, 2022

A long-time staple of ChemDraw, HOTKEYS – single keyboard key presses over an atom or a bond to elicit an action.

Read More

Spotlight

Juno Therapeutics, Inc.

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date.

Events